Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 28 tags : Treatment save search
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 0.68%
C: -0.26%
CNSP A | $0.1975 -3.38% 51K
|
Health Technology
|
| O: 8.65%
H: 0.0%
C: -6.34%
treatment approval berubicin potential glioblastoma
USD 438.03 Mn growth expected in Krabbe Disease Treatment Market | North America to emerge as key market | Technavio
Published: 2022-04-28 (Crawled : 16:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: 0.0%
GLAXF | $20.2 510
|
Health Technology
|
| O: -3.19%
H: 1.56%
C: 1.56%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
NVS | News | $92.61 -0.51% 430K
|
Health Technology
|
| O: -0.38%
H: 0.0%
C: 0.0%
GSK | $39.44 -0.4% 560K
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
ABBV | $165.54 0.78% 2.2M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
america treatment disease growth market
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
Published: 2022-04-28 (Crawled : 13:00) - biospace.com/
ZYME | $8.77 -0.9% 130K
|
Health Technology
|
| O: 0.0%
H: 1.84%
C: 1.43%
treatment cancer enroll her2- her2
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
NILE 4 | $0.1225 0.0%
|
n/a
|
| O: -2.93%
H: 3.88%
C: 0.64%
ALZN | $0.7241 6.9K
|
Professional, Scientific, and T...
|
| O: 5.59%
H: 1.6%
C: -2.25%
al001 treatment dementia trial alzheimer’s phase 1 alzheimer's
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
NILE 4 | $0.1225 0.0%
|
n/a
|
| O: -2.93%
H: 3.88%
C: 0.64%
ALZN | $0.7241 6.9K
|
Professional, Scientific, and T...
|
| O: 5.59%
H: 1.6%
C: -2.25%
al001 treatment dementia trial alzheimer’s phase 1 alzheimer's
Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 4.44%
H: 1.53%
C: 0.43%
tst002 treatment antibody china osteoporosis
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
Published: 2022-04-28 (Crawled : 10:00) - biospace.com/
CARA | $0.6998 -4.39% 86K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -7.09%
kapruvia treatment hemodialysis
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
INVO | $1.36 78.95% 3.6M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.